Compounds > fludarabine

fludarabine and treosulfan

fludarabine has been researched along with treosulfan in 65 studies

Research

Studies (65)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's13 (20.00)29.6817
2010's34 (52.31)24.3611
2020's18 (27.69)2.80

Authors

AuthorsStudies
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M1
Casper, J; Dölken, G; Freund, M; Hammer, U; Hartung, G; Kiefer, T; Kleine, HD; Knauf, W; Knopp, A; Steiner, B; Wegener, R; Wilhelm, S; Wolff, D1
Aschan, J; Blau, I; Casper, J; Doelken, G; Freund, M; Giebel, S; Holowiecki, J; Knauf, W; Kroger, N; Ruutu, T; Schafer-Eckart, K; Volin, L; Wandt, H; Zander, A1
Baumgart, J; Casper, J; Freund, M; Grobe, N; Hähling, D; Hartung, G; Hilgendorf, I; Junghanss, C; Kahl, C; Lück, A; Pichlmeier, U; Steiner, B; Wilhelm, S; Wolff, D1
Atanackovic, D; Ayuk, F; Dahlke, J; Kröger, N; Nagler, A; Panse, J; Renges, H; Schieder, H; Shimoni, A; Wolschke, C; Zabelina, T; Zander, A1
Hanke, A; Lohse, P; Meissner, B; Rehe, K; Sauer, M; Sykora, KW; Welte, K; Zeidler, C1
Andreesen, R; Beelen, DW; Blau, IW; Casper, J; Einsele, H; Fauser, AA; Fietz, T; Freund, M; Hopfenmüller, W; Kanz, L; Keilholz, U; Knauf, W; Marinets, O; Ruutu, T; Schmidt-Hieber, M; Stuhler, G; Thiel, E; Trenschel, R; Uharek, L; Volin, L1
Blau, IW; Blau, O; Göldner, H; Hopfenmüller, W; Knauf, W; Leschinger, N; Schmidt-Hieber, M; Thiel, E1
Hardan, I; Nagler, A; Rand, A; Shem-Tov, N; Shimoni, A; Yerushalmi, R1
Esser, R; Kalaäoui, RE; Klingebiel, T; Kloess, S; Koehl, U; Kreuter, J; Lehrnbecher, T; Munkelt, D; Schubert, R; Schwabe, D; Wehner, S; Zimmermann, SY1
Casper, J; Freund, M; Giebel, S; Holowiecka-Goral, A; Holowiecki, J; Krawczyk-Kulis, M; Markiewicz, M; Wojnar, J1
Angelucci, E; Baronciani, D; Depau, C; Di Bartolomeo, P; Iori, AP; Mico, C; Pettinau, M; Pilo, F; Rambaldi, A; Santarone, S1
Bernardo, ME; Caocci, G; Comoli, P; Cugno, C; Giorgiani, G; La Nasa, G; Locatelli, F; Mastronuzzi, A; Merli, P; Piras, E; Vacca, A; Zecca, M1
Aschan, J; Baumgart, J; Blau, IW; Casper, J; Freund, M; Giebel, S; Hilgendorf, I; Holowiecki, J; Knauf, W; Kröger, N; Mylius, HA; Pichlmeier, U; Ruutu, T; Schäfer-Eckart, K; Volin, L; Wandt, H; Wolff, D; Zander, AR1
Appelbaum, FR; Bedalov, A; Deeg, HJ; Doney, KC; Flowers, ME; Guthrie, KA; Hilger, RA; Kovacsovics, TJ; Maziarz, RT; Nemecek, ER; Pagel, JM; Sanders, JE; Scott, BL; Sickle, EJ; Sorror, ML; Witherspoon, R; Wood, BL; Woolfrey, AE1
Choma, M; Chybicka, A; Cornish, J; Gorczyńska, E; Grund, G; Kowalczyk, JR; Peters, C; Sykora, KW; Wachowiak, J1
Baumgart, J; Beelen, DW; Blau, IW; Casper, J; Einsele, H; Finke, J; Freund, M; Giebel, S; Gramatzki, M; Holowiecki, J; Kienast, J; Larsson, K; Markiewicz, M; Mylius, HA; Pichlmeier, U; Repp, R; Ruutu, T; Schnitzler, M; Stelljes, M; Stuhler, G; Trenschel, R; Uharek, L; Volin, L; Zander, AR1
Anne, N; Eeva, J; Heli, U; Liisa, V; Tapani, R1
Baumgart, J; Beelen, DW; Blau, I; Bornhaeuser, M; Casper, J; Einsele, H; Freund, M; Giebel, S; Holowiecki, J; Kruzel, T; Larsson, K; Markiewicz, M; Mylius, HA; Pichlmeier, U; Ruutu, T; Schaefer-Eckart, K; Stuhler, G; Trenschel, R; Uharek, L; Volin, L; Wandt, H; Zander, AR1
Danylesko, I; Nagler, A; Shem-Tov, N; Shimoni, A; Volchek, Y; Yerushalmi, R1
Bernardo, ME; Bertaina, A; Caocci, G; Contoli, B; Giorgiani, G; La Nasa, G; Locatelli, F; Mastronuzzi, A; Pagliara, D; Pinto, RM; Piras, E; Vacca, A; Zecca, M1
Galaup, A; Paci, A1
Choudhary, D; Gupta, N; Handoo, A; Katewa, S; Kharya, G; Pavecha, P; Setia, R; Sharma, SK1
Appelbaum, FR; Bar, M; Baumgart, J; Deeg, HJ; Delaney, C; Estey, EH; Fang, M; Gutman, J; Gyurkocza, B; Maziarz, RT; Milano, F; Nemecek, ER; Pagel, JM; Ramakrishnan, A; Sandmaier, BM; Scott, B; Storer, BE; Wood, B1
Dahllöf, G; Heimdahl, A; Legert, KG; Remberger, M; Ringdén, O1
Assanelli, A; Battaglia, M; Bernardi, M; Bondanza, A; Bonini, C; Bordignon, C; Carbone, MR; Carrabba, M; Ciceri, F; Clerici, D; Corti, C; Crocchiolo, R; Crotta, A; Crucitti, L; Ferraro, A; Fleischhauer, K; Forcina, A; Giglio, F; Guggiari, E; Locatelli, F; Lorusso, A; Lunghi, F; Marcatti, M; Marktel, S; Mastaglio, S; Messina, C; Noviello, M; Olek, S; Oliveira, G; Patriarca, F; Peccatori, J; Roncarolo, MG; Rossini, S; Stanghellini, MT; Tassara, M; Vago, L; Zecca, M1
Benesch, M; Brunner-Krainz, M; Lackner, H; Paschke, E; Plecko, B; Raicht, A; Schwinger, W; Seidel, M; Sovinz, P; Sperl, D; Strenger, V; Urban, C1
Baker, KS; Burroughs, LM; Deeg, HJ; Delaney, C; Domm, J; Englund, JA; Flowers, ME; Giller, RH; Nemecek, ER; Rawlings, DJ; Shimamura, A; Skoda-Smith, S; Storb, R; Storer, BE; Talano, JA; Thakar, MS; Torgerson, TR; Woolfrey, AE1
Dinur-Schejter, Y; Erlich, O; Gorelik, N; Krauss, AC; Porat, I; Stein, J; Stepensky, P; Weintraub, M; Yahel, A; Zaidman, I1
Assanelli, A; Bernardi, M; Carrabba, M; Ciceri, F; Claudiani, S; Corti, C; De Freitas, T; Giglio, F; Guggiari, E; Lunghi, F; Lupo-Stanghellini, MT; Marcatti, M; Marktel, S; Peccatori, J; Piemontese, S1
Aljurf, MD; Arat, M; Bader, P; Boelens, JJ; Duarte, R; Faraci, M; Lawitschka, A; Peters, C; Socie, G; Tichelli, A; Veys, P; Wachowiak, J; Yaniv, I1
Angelucci, E; Baronciani, D; Culurgioni, F; Depau, C; Derudas, D; Latte, G; Palmas, A; Tandurella, I; Targhetta, C1
Avigdor, A; Danylesko, I; Nagler, A; Shem-Tov, N; Shimoni, A; Yerushalmi, R1
Boztug, H; Cant, A; Glogova, E; Lankester, A; Peters, C; Pötschger, U; Skinner, R; Slatter, M; Sykora, KW; Veys, P; Wachowiak, J; Zecca, M1
Byrne, JA; Earl, JW; Fraser, CJ; Koyyalamudi, SR; Kuzhiumparambil, U; Nath, CE; O'Brien, TA; Shaw, PJ1
Crazzolara, R; Haas, OA; Kager, L; Kropshofer, G; Matthes-Martin, S1
Apel, A; Bernardi, M; Bonini, C; Ciceri, F; Danylesko, I; Greco, R; Lo Russo, A; Lupo Stanghellini, MT; Nagler, A; Peccatori, J; Shem-Tov, N; Shimoni, A; Vago, L; Yerushalmi, R1
Delaney, C; Gammill, H; Kanaan, SB; Milano, F; Nelson, JL; Oliver, DC1
Björklund, A; Garming-Legert, K; Hassan, M; Ljungman, P; Mattsson, J; Remberger, M; Serafi, IE; Sundin, M; Törlen, J1
Abd Hamid, IJ; Abinun, M; Amrolia, P; Cant, AJ; Chiesa, R; Elfeky, R; Flood, T; Gaspar, HB; Gennery, AR; Hambleton, S; Nademi, Z; Pearce, MS; Qasim, W; Rao, K; Slatter, MA; Veys, P; Worth, A1
Algeri, M; Aricò, M; Basso, G; Caniglia, M; Cesaro, S; Di Bartolomeo, P; Fagioli, F; Favre, C; Giardino, S; Locatelli, F; Marzollo, A; Merli, P; Messina, C; Pillon, M; Porta, F; Prete, A; Rabusin, M; Ripaldi, M; Rovelli, A; Saglio, F; Sieni, E; Zecca, M; Ziino, O1
Avni, B; Grisariu, S; Hussein, F; Lokshin, E; NaserEddin, A; Oron, HC; Shadur, B; Stepensky, P; Zaidman, I1
Bredius, RGM; Bresters, D; Jacobse, J; Kollen, WJW; Mensink, H; van der Stoep-Yap, MYEC1
Bittenbring, J; Brecht, A; Canaani, J; Ganser, A; Labopin, M; Labussière-Wallet, H; Mayer, J; Mohty, M; Nagler, A; Savani, B; Sheth, V; Shouval, R; Volin, L1
Beelen, D; Bochtler, T; Brecht, A; Bunjes, D; Eder, M; Einsele, H; Kröger, N; Labopin, M; Labussière-Wallet, H; Mohty, M; Nagler, A; Niederwieser, D; Saraceni, F; Savani, BN; Tischer, J1
Behre, G; Döhring, C; Franke, GN; Grimm, J; Hille, A; Jentzsch, M; Linke, R; Niederwieser, D; Pönisch, W; Schwind, S; Vucinic, V1
Shimoni, A1
Gennery, AR; Hoenig, M; Lum, SH; Slatter, MA1
Altman Kohl, S; Even-Or, E; Molho-Pessach, V; Stepensky, P; Zaidman, I1
Bąbol-Pokora, K; Dąbrowska-Leonik, N; Frączkiewicz, J; Gul, K; Janeczko-Czarnecka, M; Kałwak, K; Martuszewski, A; Mielcarek-Siedziuk, M; Młynarski, W; Nowak, M; Paluszkiewicz, P; Salamonowicz-Bodzioch, M; Sierżęga-Staykov, K; Ussowicz, M; Wawrzyniak-Dzierżek, E; Wolska-Kuśnierz, B1
Dreger, P; Hegenbart, U; Herfarth, K; Luft, T; Müller-Tidow, C; Radujkovic, A1
Andersen, NS; Friis, LS; Grønbæk, K; Hansen, JW; Kornblit, B; Petersen, SL; Schjødt, I; Sengeløv, H; Wedge, E1
Ussowicz, M1
Bansal, M; Bhargava, R; Chakraborty, S; Dua, V; Hamal, S; Sachdev, M1
Aleinikova, O; Ansari, M; Ariffin, H; Bader, P; Balduzzi, A; Bierings, M; Buechner, J; Burkhardt, B; Corbacioglu, S; Dalle, JH; Diaz-de-Heredia, C; Essa, M; Güngör, T; Ifversen, M; Lankester, A; Locatelli, F; Meisel, R; Peters, C; Pichler, H; Poetschger, U; Schrappe, M; Schultz, K; Sedlacek, P; Shaw, PJ; Staciuk, R; Stein, J; Svec, P; Toporski, J; Truong, TH; Vettenranta, K; von Stackelberg, A1
Beelen, D; Bethge, W; Blaise, D; Chevallier, P; Ciceri, F; de Witte, T; Ganser, A; Iacobelli, S; Koster, L; Kröger, N; Luft, T; Mufti, GJ; Nagler, A; Robin, M; Schwerdtfeger, R; Shimoni, A; Volin, L; Yakoub-Agha, I1
Casper, J; Frietsch, JJ; Hilgendorf, I; Hochhaus, A; Köhne, CH; O'Hagan Henderson, S1
Algeri, M; Alseraihy, A; Angelucci, E; Corbacioglu, S; Cseh, A; de la Fuente, J; Fisgin, T; Galimard, JE; Isgrò, A; Kleinschmidt, K; La La Nasa, G; Lankester, A; Locatelli, F; Lüftinger, R; Peters, C; Salzer, E; Smiers, FJ; Unal, E; Yesilipek, A; Zecca, M; Zubarovskaya, N1
Bassermann, F; Braitsch, K; Götze, KS; Herhaus, P; Hubbuch, M; Keller, U; Koch, K; Menzel, H; Schwarz, A; Verbeek, M1
Crodel, CC; Frietsch, JJ; Hilgendorf, I; Hochhaus, A; Linke, P; Miethke, J; Schnetzke, U; Scholl, S1
Abraham, A; Balasubramanian, P; Devasia, AJ; Fouzia, NA; George, B; Kavitha, ML; Korula, A; Kulkarni, UP; Lionel, S; Mathews, V; Pai, AA; Selvarajan, S; Sindhuvi, E; Srivastava, A1
Bertz, H; Bornhäuser, M; Burchert, A; Dreger, P; Finke, J; Glass, B; Grishina, O; Hegenbart, U; Kobbe, G; Reicherts, C; Schmoor, C; Schub, N; Sohlbach, K; Stelljes, M; Wagner-Drouet, EM1
Bazarbachi, A; Bethge, W; Bug, G; Carlson, K; Hilgendorf, I; Kaare, A; Kröger, N; Labopin, M; Mielke, S; Mohty, M; Nagler, A; Niittyvuopio, R; Reinhardt, HC; Savani, BN; Schäfer-Eckart, K; Spyridonidis, A; Stelljes, M; Verbeek, M1
Bagnoli, F; Barbullushi, K; Bellani, V; Cassanello, G; Cavallaro, F; Galassi, G; Goldaniga, M; Onida, F; Saporiti, G; Serpenti, F1
Carlow, DC; Hutcherson, SM; Schofield, RC1

Reviews

2 review(s) available for fludarabine and treosulfan

ArticleYear
Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan.
    Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:3

    Topics: Administration, Oral; Animals; Antineoplastic Agents, Alkylating; Busulfan; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Liver; Myeloablative Agonists; Ovarian Neoplasms; Vidarabine; Whole-Body Irradiation

2013
Conditioning Regimens for Hematopoietic Cell Transplantation in Primary Immunodeficiency.
    Current allergy and asthma reports, 2019, 11-18, Volume: 19, Issue:11

    Topics: Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Primary Immunodeficiency Diseases; Transplantation Conditioning; Vidarabine

2019

Trials

21 trial(s) available for fludarabine and treosulfan

ArticleYear
Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation.
    Blood, 2004, Jan-15, Volume: 103, Issue:2

    Topics: Acute Disease; Adult; Aged; Alkylating Agents; Busulfan; Chronic Disease; Family; Female; Histocompatibility Testing; Humans; Immunosuppressive Agents; Leukemia; Living Donors; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2004
Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation.
    Annals of hematology, 2004, Volume: 83 Suppl 1

    Topics: Busulfan; Humans; Leukemia; Leukemia, Myeloid, Acute; Leukocyte Transfusion; Lymphoma; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2004
Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
    Bone marrow transplantation, 2006, Volume: 37, Issue:4

    Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Recurrence; Siblings; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2006
Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome.
    Bone marrow transplantation, 2007, Volume: 39, Issue:3

    Topics: Abnormalities, Multiple; Adolescent; Bone Marrow Diseases; Busulfan; Child; Child, Preschool; Cyclophosphamide; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Melphalan; Pilot Projects; Syndrome; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2007
Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia.
    British journal of haematology, 2008, Volume: 142, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2008
Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients.
    American journal of hematology, 2008, Volume: 83, Issue:9

    Topics: Adolescent; Adult; Aged; Busulfan; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Comorbidity; Digestive System Diseases; Feasibility Studies; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Kidney Diseases; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Reoperation; Risk; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2008
Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major.
    British journal of haematology, 2008, Volume: 143, Issue:4

    Topics: Adolescent; Adult; beta-Thalassemia; Busulfan; Child; Child, Preschool; Drug Therapy, Combination; Female; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Thiotepa; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2008
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult

2011
Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party.
    Bone marrow transplantation, 2011, Volume: 46, Issue:12

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematologic Neoplasms; Humans; Infant; Male; Melphalan; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2011
Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.
    Haematologica, 2011, Volume: 96, Issue:9

    Topics: Adult; Antineoplastic Agents; Busulfan; Chimerism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2011
Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning.
    Bone marrow transplantation, 2012, Volume: 47, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2012
Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity.
    Bone marrow transplantation, 2012, Volume: 47, Issue:10

    Topics: Adult; Aged; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2012
Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan.
    Blood, 2012, Jul-12, Volume: 120, Issue:2

    Topics: Adolescent; Adult; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cohort Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Risk Factors; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2012
Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:4

    Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Neoplasm, Residual; Prospective Studies; Recurrence; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2014
Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors.
    Leukemia, 2015, Volume: 29, Issue:2

    Topics: Administration, Oral; Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum; Blood Platelets; Busulfan; Child; Female; Graft vs Host Disease; HLA Antigens; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Neutrophils; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Rituximab; Sirolimus; T-Lymphocytes; T-Lymphocytes, Regulatory; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2015
Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:12

    Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Fanconi Anemia; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Methotrexate; Myeloablative Agonists; Prospective Studies; Tacrolimus; Transplantation Conditioning; Unrelated Donors; Vidarabine

2014
Treosulfan-fludarabine-thiotepa conditioning before allogeneic haemopoietic stem cell transplantation for patients with advanced lympho-proliferative disease. A single centre study.
    Hematological oncology, 2016, Volume: 34, Issue:1

    Topics: Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Salvage Therapy; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2016
Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies.
    Bone marrow transplantation, 2015, Volume: 50, Issue:12

    Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma; Male; Middle Aged; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Vidarabine

2015
Treosulfan and Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Children with Primary Immunodeficiency: UK Experience.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:3

    Topics: Adolescent; Adult; Alemtuzumab; Allografts; Busulfan; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Infant; Male; Risk Factors; Survival Rate; Transplantation Conditioning; United Kingdom; Vidarabine

2018
Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 02-01, Volume: 39, Issue:4

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemoradiotherapy; Child; Child, Preschool; Equivalence Trials as Topic; Etoposide; Female; Follow-Up Studies; Humans; International Agencies; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Survival Rate; Thiotepa; Vidarabine; Whole-Body Irradiation

2021
Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial.
    Bone marrow transplantation, 2022, Volume: 57, Issue:11

    Topics: Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Retrospective Studies; Thiotepa; Transplantation Conditioning; Unrelated Donors; Vidarabine

2022

Other Studies

42 other study(ies) available for fludarabine and treosulfan

ArticleYear
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
    Journal of medicinal chemistry, 2008, Nov-13, Volume: 51, Issue:21

    Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship

2008
[Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine].
    Deutsche medizinische Wochenschrift (1946), 2005, Sep-23, Volume: 130, Issue:38

    Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Recurrence; Regression Analysis; Remission Induction; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2005
Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma.
    Bone marrow transplantation, 2007, Volume: 39, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2007
Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
    Annals of hematology, 2007, Volume: 86, Issue:8

    Topics: Adolescent; Adult; Aged; Busulfan; Chimerism; Female; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2007
Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:12

    Topics: Adult; Aged; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2007
Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients.
    Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Busulfan; Caspase 3; Cell Line, Tumor; Child; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Killer Cells, Natural; Leukemia; Stem Cells; T-Lymphocytes; Tetrazolium Salts; Thiazoles; Vidarabine

2008
Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Adolescent; Adult; Busulfan; Drug Therapy, Combination; Feasibility Studies; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2010
Low incidence and severity of oral mucositis in allogeneic stem cell transplantation after conditioning with treosulfan and fludarabine.
    European journal of haematology, 2012, Volume: 88, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Female; Hematologic Neoplasms; Humans; Incidence; Male; Middle Aged; Mucositis; Myeloablative Agonists; Severity of Illness Index; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2012
Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:3

    Topics: Adolescent; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; India; Male; Myeloablative Agonists; Retrospective Studies; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2013
Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014, Volume: 22, Issue:8

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosphamide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multivariate Analysis; Oral Hygiene; Prednisone; Sirolimus; Stomatitis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult

2014
Unrelated CD3/CD19-depleted peripheral stem cell transplantation for Hurler syndrome.
    Pediatric hematology and oncology, 2014, Volume: 31, Issue:8

    Topics: Antigens, CD19; Antineoplastic Agents, Alkylating; Busulfan; CD3 Complex; Chimerism; Drug-Related Side Effects and Adverse Reactions; Female; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphocyte Depletion; Male; Mucopolysaccharidosis I; Peripheral Blood Stem Cell Transplantation; Quality of Life; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2014
Bone marrow transplantation for non-malignant diseases using treosulfan-based conditioning.
    Pediatric blood & cancer, 2015, Volume: 62, Issue:2

    Topics: Adolescent; Alkylating Agents; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Retrospective Studies; Thiotepa; Vidarabine

2015
Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis.
    Hematological oncology, 2016, Volume: 34, Issue:3

    Topics: Aged; Allografts; Busulfan; Disease-Free Survival; Female; Humans; Male; Middle Aged; Primary Myelofibrosis; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Unrelated Donors; Vidarabine

2016
Paediatric reduced intensity conditioning: analysis of centre strategies on regimens and definitions by the EBMT Paediatric Diseases and Complications and Quality of Life WP.
    Bone marrow transplantation, 2015, Volume: 50, Issue:4

    Topics: Adolescent; Allografts; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Databases, Factual; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Quality of Health Care; Quality of Life; Retrospective Studies; Transplantation Conditioning; Vidarabine

2015
European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.
    Pediatric blood & cancer, 2016, Volume: 63, Issue:1

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Blood Transfusion; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Europe; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia; Male; Multivariate Analysis; Retrospective Studies; Societies, Medical; Transplantation Conditioning; Treatment Outcome; Vidarabine

2016
Development and Validation of a High Pressure Liquid Chromatography-UV Method for the Determination of Treosulfan and Its Epoxy Metabolites in Human Plasma and Its Application in Pharmacokinetic Studies.
    Journal of chromatographic science, 2016, Volume: 54, Issue:3

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Biphenyl Compounds; Busulfan; Child; Child, Preschool; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Ditiocarb; Epoxy Compounds; Female; Humans; Infant; Male; Methanol; Prodrugs; Reference Standards; Solvents; Vidarabine; Water

2016
Reduced-intensity conditioning and stem cell transplantation in infants with Diamond Blackfan anemia.
    Haematologica, 2017, Volume: 102, Issue:3

    Topics: Anemia, Diamond-Blackfan; Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Male; Myeloablative Agonists; Thiotepa; Transplantation Conditioning; Treatment Outcome; Vidarabine

2017
Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning.
    American journal of hematology, 2017, Volume: 92, Issue:10

    Topics: Adult; Aged; Busulfan; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Genotype; Hematopoietic Stem Cell Transplantation; HLA-C Antigens; Humans; Leukemia, Myeloid, Acute; Ligands; Male; Middle Aged; Myelodysplastic Syndromes; Receptors, KIR; Recurrence; Retrospective Studies; Siblings; Transplantation Conditioning; Unrelated Donors; Vidarabine; Young Adult

2017
Persistence of the losing cord blood unit following double cord blood transplantation: finding the unseen.
    Blood, 2017, 09-21, Volume: 130, Issue:12

    Topics: Adolescent; Adult; Blood Cells; Bone Marrow Cells; Busulfan; Child; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft Survival; Hematopoiesis; Humans; Immunosuppressive Agents; Male; Middle Aged; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult

2017
Toxicological effects of fludarabine and treosulfan conditioning before allogeneic stem-cell transplantation.
    International journal of hematology, 2017, Volume: 106, Issue:4

    Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Child; Child, Preschool; Cystitis; Female; Hematopoietic Stem Cell Transplantation; Hemorrhage; Humans; Infant; Male; Middle Aged; Transplantation Conditioning; Vascular Diseases; Vidarabine

2017
Outcomes of Children with Hemophagocytic Lymphohistiocytosis Given Allogeneic Hematopoietic Stem Cell Transplantation in Italy.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:6

    Topics: Adolescent; Busulfan; Child; Child, Preschool; Female; Graft Rejection; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Infant; Italy; Lymphohistiocytosis, Hemophagocytic; Male; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2018
Successful hematopoietic stem cell transplantation for osteopetrosis using reduced intensity conditioning.
    Pediatric blood & cancer, 2018, Volume: 65, Issue:6

    Topics: Adolescent; Adult; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Male; Melphalan; Myeloablative Agonists; Osteopetrosis; Prognosis; Retrospective Studies; Transplantation Conditioning; Vidarabine; Young Adult

2018
Long-term aprepitant for nausea and vomiting associated with gastroparesis in hematopoietic stem cell transplantation.
    Bone marrow transplantation, 2018, Volume: 53, Issue:10

    Topics: Alemtuzumab; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Busulfan; Cyclosporine; Gastroparesis; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphohistiocytosis, Hemophagocytic; Male; Methotrexate; Nausea; Unrelated Donors; Vidarabine; Vomiting

2018
Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis.
    Bone marrow transplantation, 2019, Volume: 54, Issue:4

    Topics: Aged; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Transplantation Conditioning; Vidarabine

2019
Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and
    Journal of hematology & oncology, 2019, 04-25, Volume: 12, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Europe; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult

2019
Comparison of non-myeloablative and reduced-intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes.
    American journal of hematology, 2019, Volume: 94, Issue:12

    Topics: Age Factors; Aged; Aged, 80 and over; Busulfan; Comorbidity; Graft vs Host Disease; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Myeloproliferative Disorders; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Recurrence; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2019
Treosulfan-based or busulfan-based conditioning for allogeneic transplantation: the role of dose intensity.
    The Lancet. Haematology, 2020, Volume: 7, Issue:1

    Topics: Busulfan; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Transplantation, Homologous; Vidarabine

2020
Skin toxicity following treosulfan-thiotepa-fludarabine-based conditioning regimen in non-malignant pediatric patients undergoing hematopoietic stem cell transplantation.
    Pediatric transplantation, 2020, Volume: 24, Issue:1

    Topics: Busulfan; Child; Child, Preschool; Drug Eruptions; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Prognosis; Prospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine

2020
Successful Allogeneic Stem Cell Transplantation in Nuclear Factor-Kappa B Essential Modulator Deficiency Syndrome After Treosulfan-Based Conditioning: A Case Report.
    Transplantation proceedings, 2020, Volume: 52, Issue:2

    Topics: Antilymphocyte Serum; Busulfan; Ectodermal Dysplasia; Hematopoietic Stem Cell Transplantation; Humans; I-kappa B Kinase; Immunologic Deficiency Syndromes; Infant; Male; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2020
High leukemia-free survival after TBI-based conditioning and mycophenolate mofetil-containing immunosuppression in patients allografted for chronic myelomonocytic leukemia: a single-center experience.
    Annals of hematology, 2020, Volume: 99, Issue:4

    Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Calcineurin Inhibitors; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Melphalan; Methotrexate; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Neoplasms, Second Primary; Proportional Hazards Models; Retrospective Studies; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2020
Improved Outcomes after Allogenic Hematopoietic Stem Cell Transplantation with Fludarabine/Treosulfan for Patients with Myelodysplastic Syndromes.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2020, Volume: 26, Issue:6

    Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2020
Treosulfan in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation.
    Drugs of today (Barcelona, Spain : 1998), 2020, Volume: 56, Issue:6

    Topics: Busulfan; Drug Combinations; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning; Vidarabine

2020
Haploidentical Stem Cell Transplant With Post-transplant Cyclophosphamide for Chediak-Higashi Syndrome: A Very Rare Case Report.
    Journal of pediatric hematology/oncology, 2021, Oct-01, Volume: 43, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chediak-Higashi Syndrome; Combined Modality Therapy; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Melphalan; Prognosis; Transplantation Conditioning; Vidarabine

2021
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
    British journal of haematology, 2021, Volume: 195, Issue:3

    Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Cyclophosphamide; Disease Progression; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Living Donors; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Registries; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2021
Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms.
    Journal of cancer research and clinical oncology, 2022, Volume: 148, Issue:10

    Topics: Busulfan; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine

2022
Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major.
    Annals of hematology, 2022, Volume: 101, Issue:3

    Topics: Adolescent; Antineoplastic Agents; beta-Thalassemia; Busulfan; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Myeloablative Agonists; Retrospective Studies; Transplantation Conditioning; Vidarabine

2022
Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis.
    Annals of hematology, 2022, Volume: 101, Issue:6

    Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myeloproliferative Disorders; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation Conditioning; Vidarabine

2022
Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma.
    Bone marrow transplantation, 2022, Volume: 57, Issue:7

    Topics: Aged; Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Vidarabine

2022
Endothelial Activation and Stress Index-Measured Pretransplantation Predicts Transplantation-Related Mortality in Patients with Thalassemia Major Undergoing Transplantation with Thiotepa, Treosulfan, and Fludarabine Conditioning.
    Transplantation and cellular therapy, 2022, Volume: 28, Issue:7

    Topics: Adolescent; Adult; beta-Thalassemia; Busulfan; Child; Child, Preschool; Female; Humans; Infant; Male; Retrospective Studies; Thiotepa; Vidarabine; Young Adult

2022
Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT.
    Bone marrow transplantation, 2023, Volume: 58, Issue:6

    Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2023
Treosulfan, thiotepa and fludarabine conditioning regimen prior to first allogeneic stem cell transplantation in acute myeloid leukemia and high-risk myelodysplastic syndromes: a single center experience.
    Bone marrow transplantation, 2023, Volume: 58, Issue:9

    Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thiotepa; Transplantation Conditioning; Vidarabine

2023
Determination of Treosulfan and Fludarabine in Plasma by Turbulent Flow Liquid Chromatography-Tandem Mass Spectrometry (TFLC-MS/MS).
    Methods in molecular biology (Clifton, N.J.), 2024, Volume: 2737

    Topics: Busulfan; Chromatography, Liquid; Humans; Tandem Mass Spectrometry

2024